Business
PureTech Showcases Differentiated IPF Strategy
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced positive Phase 2b ELEVATE IPF trial data for deupirfenidone (LYT-100), a potential new standard of care in idiopathic pulmonary fibrosis (IPF). The trial, lasting 26 weeks, showed a statistically significant reduction in lung function decline (-21.5 mL) at 26 weeks with deupirfenidone 825 mg three times a day (TID) compared to placebo (-112.5 mL) and pirfenidone (-51.6 mL). The treatment effect with deupirfenidone was approximately 50% greater than pirfenidone compared to placebo. Open-label extension data showed sustained treatment effect for at least 52 weeks (-32.8 mL decline in FVC). Patient preference data indicated 69% of participants prioritized efficacy over tolerability, and 94% would discuss a new treatment with their physician. Development of deupirfenidone will be advanced by Celea Therapeutics, a newly launched PureTech Founded Entity. Disclaimer*
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n21 August 2025\nPureTech Health plc\n \nPureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF\n \nDeupirfenidone to be advanced by PureTech's newly launched Founded Entity, Celea Therapeutics\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, demonstrated its growing leadership in idiopathic pulmonary fibrosis (IPF) at the 2025 IPF Summit this week in Boston. The Company highlighted the strength of its Phase 2b ELEVATE IPF trial data supporting the advancement of deupirfenidone (LYT-100) into Phase 3 by its newest Founded Entity, Celea Therapeutics (\"Celea\"), and shared new patient preference data and insights shaped by deep engagement across the IPF treatment ecosystem.\n \n\"With deupirfenidone demonstrating compelling efficacy, we are taking a holistic approach to Phase 3 planning - one that is informed by a deep understanding of the needs of patients, clinicians, and payers alike,\" said Camilla Graham, MD, MPH, Senior Vice President of Medical Affairs at PureTech. \"After more than a decade without meaningful therapeutic advancement, the IPF treatment landscape is beginning to shift. To deliver real impact, innovation must extend beyond the molecule - into clinical trial design, patient and provider education, and access. That's the bar we've set with deupirfenidone.\"\n \nBalancing Efficacy and Safety of Treatment: Perspectives of People Living with IPF\nAs part of its commitment to developing therapies that address real-world needs, PureTech shared new findings from structured interviews with 16 individuals living with IPF, designed to understand how patients weigh the trade-offs between efficacy and tolerability when considering novel treatments. The data highlight that patients are not only open to new options, they are primarily motivated by the potential for better outcomes. Key findings included the following:\n \n· 69% of participants preferred a hypothetical treatment offering greater efficacy over one with improved tolerability.\n·  ...